Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome |
| |
Authors: | Andres Chang Danielle Schlafer Christopher R. Flowers |
| |
Affiliation: | 1. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA;2. Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA;3. Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA, USA |
| |
Abstract: | Introduction: Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. Areas covered: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response. Expert opinion: We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses. |
| |
Keywords: | PD-1 PD-L1 non-Hodgkin lymphoma Hodgkin lymphoma immunotherapy PD-1 inhibitor |
|
|